EP2411804A1 - Method for the in vitro diagnosis of stroke - Google Patents

Method for the in vitro diagnosis of stroke

Info

Publication number
EP2411804A1
EP2411804A1 EP09786393A EP09786393A EP2411804A1 EP 2411804 A1 EP2411804 A1 EP 2411804A1 EP 09786393 A EP09786393 A EP 09786393A EP 09786393 A EP09786393 A EP 09786393A EP 2411804 A1 EP2411804 A1 EP 2411804A1
Authority
EP
European Patent Office
Prior art keywords
probnp
stroke
level
ndka
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP09786393A
Other languages
German (de)
French (fr)
Other versions
EP2411804B1 (en
Inventor
Catherine Larue
Johann Guegan
Isabelle Giuliani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Rad Innovations SAS
Proteome Sciences PLC
Original Assignee
Bio Rad Innovations SAS
Electrophoretics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Rad Innovations SAS, Electrophoretics Ltd filed Critical Bio Rad Innovations SAS
Publication of EP2411804A1 publication Critical patent/EP2411804A1/en
Application granted granted Critical
Publication of EP2411804B1 publication Critical patent/EP2411804B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91235—Phosphotransferases in general with a phosphate group as acceptor (2.7.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Definitions

  • the present invention relates to methods and kits for the in vitro diagnosis of stroke.
  • Stroke also known as cerebrovascular accident (CVA) is one of the leading causes of mortality and morbidity with an estimated 700,000 patients diagnosed with stroke each year. Stroke currently ranks third in the cause of death in the U.S.A.
  • CVA cerebrovascular accident
  • stroke encompasses two widely different clinical settings which it is of the utmost importance to distinguish. Ischemic stroke is thus usually caused by the blockage of blood vessels and is best treated by clot dissolving agents, such as t-PA, within three hours of symptom onset. In contrast, hemorrhagic stroke is caused by bleeding into the brain which forbids any treatment by anti-clotting agents, which could prove fatal.
  • Transient ischemic attack (TIA, often colloquially referred to as "mini stroke") is caused by the changes in the blood supply to a particular area of the brain, resulting in brief neurologic dysfunction that persists, by definition, for less than 24 hours; if symptoms persist then it is categorized as a stroke (see e.g. Transient Ischemic Attacks: Stroke (CVA): Merck Manual Home Edition). Patients diagnosed with a TIA are sometimes said to have had a warning for an approaching stroke. If the time period of blood supply impairment lasts more than a few minutes, the nerve cells of that area of the brain die and cause permanent neurologic deficit.
  • TIA Transient ischemic attack Mount Sinai Hospital, New York. Therefore, the identification of TIA is beneficial because these patients are at increased risk of future stroke.
  • CT computed tomography
  • Magnetic resonance imaging (MRI) has been shown to be superior to CT in diagnosing acute stroke (84% sensitivity, Chalela et a/. (2007) Lancet 369:293-298), and particularly ischemic stroke.
  • MRI scanners are costly equipments and are not always available in the emergency room.
  • biochemical markers have been suggested as an aid in detecting stroke, in particular in view of the early detection of ischemic stroke.
  • S-100b (a marker of astrocytic activation) and neuron-specific enolase (NSE) are among the best characterized such markers (Jauch et al. (2006) Stroke 37:2508- 2513).
  • Heart-type fatty acid binding protein(H-FABP) has also been considered as a promising marker (Lescuyer et al. (2005) MoI. Diagn. 9:1-7). However, it seems that the discriminatory power offered by these markers individually is not sufficient to be of clinical value.
  • proBNP(1 -108) a precursor protein of 108 amino acids
  • BNP(32) or simply BNP Brain Natriuretic Peptide
  • NT-proBNP a precursor protein of proBNP(1-108)
  • BNP is a blood pressure regulatory agent which is released mainly from the left cardiac ventricle in response to volume expansion and pressure overload.
  • proBNP(1 -108) has been shown to be circulating in patients with severe heart failure (Hammerer-Lercher et al. (2008) Clinical Chemistry 54:5).
  • NDKA Nucleoside Diphosphate Kinase A
  • proBNP(1-108) had a high discriminatory power (e.g. 90% sensitivity and 85 % specificity) in stroke detection.
  • the present invention relates to a method for the in vitro diagnosis of stroke and Transient ischemic attack (TIA) in an individual, comprising the following steps:
  • NDKA nucleoside diphosphate kinase A
  • the above-defined method further comprises measuring the level of at least one marker of cardiovascular diseases.
  • the present invention also relates to a kit for diagnosing stroke, comprising:
  • At least one calibrator comprising proBNP(1 -108), or of fragment of proBNP(1 -108) which comprise a RAPRSP sequence (SEQ ID NO: 1 ), at least at a concentration of 1 pg/ml; and
  • - at least one antibody suitable for detecting NDKA and - optionally at least one calibrator comprising NDKA, at least at a concentration of 7 ng/ml.
  • the present invention also relates to the use of:
  • diagnosing or establishing a “diagnosis” relates to determining if a stroke has occurred in an individual.
  • stroke relates to all cerebrovascular accidents.
  • stroke encompasses acute and chronic stroke as well as ischemic and hemorrhagic stroke.
  • Ischemic stroke is characterized by a partial or total occlusion of cerebral vessels which may lead to infarction and necrosis of cerebral tissues supplied by these vessels.
  • TIA transient ischemic attack
  • Hemorrhagic stroke is characterized by an intracerebral haemorrhage generally from cerebral vessel rupture.
  • the stroke according to the invention is selected from the group consisting of an ischemic stroke, a hemorrhagic stroke, or a transient ischemic attack (TIA). More preferably, the stroke as intended herein is acute ischemic stroke.
  • the method of the invention provides for early stroke diagnosis.
  • Early stroke diagnosis is of particular importance in the case of ischemic stroke, since it is usually estimated that treating the occluded vessels within 3 hours of stroke symptoms onset will prevent most irreversible cerebral damages.
  • the above defined step (a) is implemented within 6 hours, more preferably within 3 hours, and most preferably within 2 hours, after the onset of at least one symptom indicative of stroke in the individual.
  • the symptoms indicative of stroke are well known to one of skill in the art and notably encompass sudden numbness or blindness, confusion, severe headaches, slurred speech, and partial paralysis.
  • proBNP(1 -108) relates to the precursor BNP(32) and of NT-proBNP. As intended herein “proBNP(1-108)” encompasses all its natural variants, however it is preferred that proBNP(1 -108) is represented by SEQ ID NO: 4.
  • proBNP(1-108) is often partially truncated, in particular it is deleted of one or more amino acids on the N-terminal side or optionally on the C-terminal side, for instance by circulating proteases, to form so-called "proBNP(1 -108) fragments".
  • An example of such a proBNP(1 -108) fragment, the proBNP(3-108) fragment produced by cleavage by a dipeptidase, is described in Lam et al. (2007) J. Am. Coll. Cardiol. 49:1193-1202. It is believed that it is not only proBNP(1 -108) which is of diagnosis value but also its various natural fragments. Accordingly, the present invention not only relies on measuring the level of proBNP(1 -108) but also the level of fragments of proBNP(1-108).
  • proBNP(1 -108) and “fragments of proBNP(1 -108)” also include any polypeptide having been subjected to at least one post-translational modification, such as phosphorylation, glycosylation or the like.
  • proBNP(1 -108) is a glycoprotein which is O-glycosylated either entirely or in part.
  • the fragments of proBNP(1-108) comprise the RAPRSP sequence (SEQ ID NO: 1 ).
  • This RAPRSP sequence harbours the site of proBNP(1 - 108) which is cleaved in vivo to yield NT-proBNP and BNP(32).
  • the RAPRSP is specific of proBNP(1 -108) and cannot be found in BNP(32) nor in NT- proBNP, which are thus excluded from the definition of the fragments of proBNP(1 - 108) according to the invention.
  • the fragments of proBNP(1 -108) according to the invention comprise a FGRKMDR sequence (SEQ ID NO: 2). This sequence is comprised in the BNP(32) part of proBNP(1 -108). Even more preferably, the fragments of proBNP(1 -108) comprise the whole sequence of BNP(32) (SEQ ID NO: 3).
  • NDKA nucleoside Diphosphate kinase A
  • kits according to the invention comprising antibodies to at least one further stroke marker and uses according to the invention of at least one further stroke marker.
  • the expression "further stroke marker” relates to any biochemical marker, other than proBNP(1-108), fragments of proBNP(1 -108) as defined above, or NDKA, which level is indicative of stroke or TIA as defined above.
  • the expression "marker of cardiovascular diseases” relates to any marker useful for detecting or diagnosing a cardiovascular diseases. Such markers are well known to one of skill in the art.
  • the marker of cardiovascular diseases is selected from the group constituted of the C reactive protein (CRP) and cardiac troponin I (cTnl). Measuring the level of a marker of cardiovascular diseases may be advantageous in the the method of the invention since it enables excluding cardiovascular diseases as a cause for variation of the level of proBNP(1 -108).
  • measuring or determining the level of proBNP(1 -108), of fragments of proBNP(1 -108), of NDKA, of the at least one further stroke marker, or of the at least one marker of cardiovascular diseases is determined using an immunoassay.
  • an “immunoassay” relates to any method wherein the level of proBNP(1 -108), of fragments of proBNP(1 -108), of NDKA, of the at least one further stroke marker, or of the at least one marker of cardiovascular diseases, is determined using at least one compound (or ligand) specifically binding thereto.
  • the compound (or ligand) specifically binding thereto can be of any type but it is preferred that it is an antibody, an aptamer, or a peptide obtained by phage display.
  • Immunoassay methods are well known to one of skill in the art and may be carried out in accordance with various formats well-known to the one skilled in the art, for example in solid or homogeneous phase, in one or two steps, by a sandwich method or by a competitive method.
  • the sandwich method in solid phase between 2 ligands one being a capture ligand and the other being a detection ligand, will be used.
  • This type of immunoassay is particularly well-known to one skilled in the art.
  • the article by Sefehan et al. (2007) CHn. Chem. 53:866-873 gives an example of a sandwich immunoassay (or immunometric assay at 2 sites) for assaying BNP(32) and proBNP(1 -108), each time using a pair of antibodies (an antibody immobilised in solid phase and an labelled antibody in detection).
  • detection means in particular a "detection ligand”.
  • a detection ligand which is labelled, is able to bind to the captured antigen, by recognising an epitopic site which is different from that recognised by the capture ligand.
  • labelled refers both to a direct labelling and to an indirect labelling (for example, by means of other ligands, themselves directly labelled, or using reagents of a labelled "affinity pair", such as, but not exclusively, the labelled avidin- biotin pair, etc.).
  • the capture ligand is preferably selected in such a way that it specifically recognises an epitope on the natural antigen of the patient, whilst the detection ligand is selected preferably in such a way that it specifically recognises another epitope on the natural antigen of the patient.
  • the capture ligand is immobilised on a solid phase.
  • solid phase microplates could be used, in particular polystyrene microplates, such as those sold by Nunc, Denmark.
  • Solid particles or beads, paramagnetic beads, such as those produced by Dynal, Merck-Eurolab (France) (under the trademark EstaporTM) and Polymer Laboratories, or even polystyrene or polypropylene test tubes, glass, plastic or silicon chips, etc. may also be used.
  • ELISA assays may be used to reveal the presence of formed antigen-antibody complexes.
  • different types of labelling of ligands in particular of antibodies are possible (radioactive, ezymatic, fluorescent, etc.).
  • the detection may also be carried out by methods based on mass accumulation, such as surface plasmon resonance (SPR), by piezo-electric detection, but also by mass spectrometry or any other methods defined as enabling the study of a ligand-antigen-type interaction in the absence of a second labelled ligand.
  • SPR surface plasmon resonance
  • an “antibody” as intended herein relates to antibodies belonging to any species, such as human, mouse, rat, rabbit, goat, or camelidae species.
  • the antibody can also be a chimeric antibody, i.e. an antibody which comprises parts originating from different species.
  • Preferred chimeric antibodies are so-called "humanized” antibodies, wherein the constant parts (C H and C L ) are of human origin and the variable parts (V H and V L ) are of another species, such as mouse for instance.
  • the antibody of the invention can be produced by any method known the man skilled in the art, such as by animal immunization, or by recombinant or synthetic methods for instance.
  • an "antibody” according to the invention also encompasses antibody fragments which comprise at least one of the paratopes of said antibody, such as Fab, F(ab') 2 , scFv fragments as well as camelidae single- chain antibodies.
  • the antibody of the invention can be a polyclonal antibody, in particular a monospecific polyclonal antibody, or a monoclonal antibody.
  • Aptamers are well-known by the one skilled in the art. Aptamers are compounds of a nucleotide, in particular a ribonucleotide or desoxyhbonucleotide, or a peptide nature able to bind specifically to a target, in particular a protein target.
  • the aptamers of a nucleotide nature and the production thereof are described, in particular, by Ellington et al. (1990) Nature 346:818-22 and Bock et al. (1992) Nature 355:564-6.
  • the aptamers of a peptide nature and the production thereof are described, in particular, by Hoppe-Seyler et al. (2000) J. MoI Med. 78:426-30.
  • “Phage display” denotes a technique for selecting polypeptide ligands expressed on the capsid of a bacteriophage and encoded by a nucleic sequence inserted into the capsid encoding gene. This method is well known by the one skilled in the art and is described, in particular, by Scott & Smith (1990) Science 249:386- 390, and Marks et a/. (1991 ) J. MoI. Biol. 222:581 -597.
  • the polypeptide obtainable by phage display is an scFv-type polypeptide (single-chain variable fragment). This technique is described, in particular, by Winter et al. (1994) Annu. Rev. Immunol. 12:433-455.
  • the above-defined immunoassay comprises an antibody targeting an epitope which comprises the RAPRSP sequence (SEQ ID NO: 1 ). More preferably, the antibody is secreted by the hybridoma deposited at the CNCM (Collection Nationale de Cultures de Microorganismes, lnstitut Pasteur, 25, rue du Dondel Roux, 75 724 Paris Cedex 15, France) under the Budapest Treaty on April 29, 2005, under reference number I-3073. Such an antibody is notably described in the international publication WO 2004/014952.
  • This antibody is advantageous, in that it enables the specific detection of proBNP(1-108) and of all the fragments of proBNP(1-108) according to the invention, with the notable exception of BNP(32), NT-proBNP and their respective fragments, thereby ensuring obtaining the full diagnosis benefits of proBNP(1-108) and its various fragments.
  • the immunoassay comprises an antibody targeting an epitope which comprises the FGRKMDR sequence. More preferably, the antibody is secreted by the hybhdoma deposited by Bio-Rad (3 boulevard Raymond Poincare, 92430 Marnes Ia Coquette, France) at the CNCM (Collection Nationale de Cultures de Microorganismes, lnstitut Pasteur, 25, rue du Dondel Roux, 75 724 Paris Cedex 15, France) under the Budapest Treaty on April 13, 2007, under reference number I- 3746.
  • Such an antibody is notably described in international application PCT/EP2008/060188.
  • the antibody targeting an epitope which comprises the RAPRSP sequence (SEQ ID NO: 1 ) and the antibody targeting an epitope which comprises the FGRKMDR sequence are combined in a same immunoassay, thereby enabling the specific detection of proBNP(1 -108) or of fragments of proBNP(1 -108) according to the invention.
  • NDKA level is measured using an ELISA method as generally described in international application WO 2005/029088 and in Allard et a/. (2005) Clin. Chem. 51 :2043-2051.
  • the cut-off value as defined above is of at least the mean level of proBNP(1-108), or of fragments of proBNP(1 -108) according to the invention in biological samples obtained from an apparently healthy population of individuals. More preferably, the above-defined cut-off value is of at least the value corresponding to the 75th percentile, the 95th percentile, or the 99th percentile of the levels of proBNP(1 -108), or of fragments of proBNP(1 -108) according to the invention obtained from an apparently healthy population of individuals. Most preferably, this cut-off value is of at least 0, 1 , 2, 3, 5, 10, 50 or 100 pg/ml.
  • the above defined steps a) and b) of the method of the invention consist simply in determining whether proBNP(1 -108), or fragments of proBNP(1-108), as defined above are present in the biological sample of the individual.
  • the cut-off value as defined above is preferably of at least the mean level of NDKA in biological samples obtained from an apparently healthy population of individuals. More preferably, the above-defined cutoff value is of at least the value corresponding to the 75th percentile, the 95th percentile, or the 99th percentile of the levels of NDKA obtained from an apparently healthy population of individuals. Most preferably, this cut-off value is of at least 5, 10, 15, or 20 ng/ml.
  • the cut-off value as defined above is preferably of at least the mean level of said at least one further stroke marker in biological samples obtained from an apparently healthy population of individuals.
  • the level of proBNP(1 -108), or of fragments of proBNP(1 -108), and the level of the at least one further stroke marker are compared with one or several cutoff values, this means that the level of proBNP(1 -108), or of fragments of proBNP(1 - 108), on one hand, and the level of the at least one further stroke marker, on the other hand, can be each compared to respective cut-off values, or that they can be both compared to a single cut-off value.
  • the level of NDKA (and optionally also that of the at least one further stroke marker or marker of cardiovascular diseases) is measured in the same biological sample as that in which the level of proBNP(1 -108), or of fragments of proBNP(1 -108), is measured.
  • biological sample includes both the sample as taken and the sample which has been subjected to various treatments, in particular to render it suitable for use in the processes and methods according to the invention.
  • the biological sample according to the invention can be of any type, however it is preferred that the biological sample is selected from the group constituted of a blood sample, a serum sample, a plasma sample, a cerebrospinal fluid sample, a urine sample and a saliva sample. Examples
  • proBNP(1-108) and NDKA were determined in 70 serum samples obtained from individuals in whom a stroke has occurred less than 3 hours after onset (15 hemorrhagic stroke samples (HM) and 55 ischemic stroke samples (IM)) and in 148 control serum samples from apparently healthy individuals.
  • the proBNP(1 -108) level was determined using the BioPlexTM2200 proBNP(1 -108) assay (Bio-Rad).
  • the BioPlexTM2200 combines multiplex, magnetic bead and flow cytometry technologies to provide multi-analyte detection on a fully automated random access platform.
  • Magnetic particles (8 ⁇ m diameter, carboxyl-modified surface) are dyed with 2 fluorophores (classification dyes, CL1 and CL2) which emit at distinct wavelengths and adsorb significantly at 635 nm.
  • the reporter fluorophore, ⁇ -phycoerythrin (PE) was chosen for its high molar extinction coefficient, quantum yield, resistance to photobleaching, lack of self-quenching and stability.
  • the detector simultaneously measures light at 3 wavelengths: the 2 classification dyes and the reporter dye.
  • the BioPlexTM2200 proBNP(1 -108) assay is a two-step sandwich fluorescence immunoassay.
  • the BioPlexTM2200 system combines 50 ⁇ l_ of patient sample, magnetic dyed beads coated with the anti-proBNP(1 -108) monoclonal antibody secreted by the hybhdoma deposited at the CNCM under reference number I-3073 and assay buffer into a reaction vessel.
  • anti-human BNP monoclonal antibody secreted by the hybridoma deposited at the CNCM under reference number I-3746 conjugated to phycoerythrin (PE) is added and incubated for 2 minutes.
  • PE phycoerythrin
  • the bead mixture is passed through the detector which identifies the dyed beads and the amount of antigens captured on the beads by the fluorescence of PE. After calibration using a set of 6 distinct calibrators, the 3 levels of quality controls and patient samples results are expressed in pg/mL. Two Quality Control beads are also tested with each sample to enhance the integrity of the overall system.
  • the NDKA level was determined using an ELISA method as generally described in international application WO 2005/029088 and in Allard et a/. (2005) Clin. Chem. 51 :2043-2051.
  • boxplot representation is a convenient way of graphically depicting groups of numerical data through their five-number summaries (the smallest observation, lower quartile (Q1 ), median (Q2), upper quartile (Q3), and largest observation).
  • the diagnostic performance of the markers was characterized by two indices: sensitivity (ability to detect the diseased population) and specificity (ability to detect the control population).
  • the result of a diagnostic test can be further characterized by determining the area under the curve (AUC) of a ROC (receiver operating characteristic) analysis.
  • the ROC curves are a graphical visualization of the reciprocal relation between the sensitivity (Se) and the specificity (Sp) of a test for various concentrations (M. H. Zweig and G. Campbell (1993). "Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine". Clinical chemistry 39 (8): 561-57).
  • mROC Multivariate ROC curve analysis
  • Marker combination cut-off a x Markeri + b x Marker2 where a and b are calculated coefficients and Markeri and Marker2 are individual marker cut-off values.
  • Table 2 Receiving-Operation-Characteristic analysis data for NDKA for Stroke patients when compared to Control subjects
  • the NDKA marker has a high discriminatory power in the prediction of stroke with a sensitivity of 90%, a specificity of 91.7% (Area Under the ROC curve (AUC): 0.952). Moreover, this discriminatory power is very high for both the ischemic and the hemorrhagic stroke patients compared to the control subjects.
  • Table 3 Receiving-Operation-Characteristic analysis data for proBNP for Stroke patients when compared to Control subjects
  • the proBNP marker has a high discriminatory power in the prediction of cerebrovascular accident with a sensitivity of 88%, a specificity of 93.8% and an area under the ROC curve (AUC) of 0.952. Moreover, this discriminatory power is very high for both the ischemic and the hemorrhagic stroke patients compared to the control subjects with respective AUC of 0.95 and 0.962. c) Multivariate ROC curve analysis
  • Table 4 Multivariate Receiving-Operation-Characteristic analysis data for the NDKA and proBNP combination for Stroke patients when compared to Control subjects
  • the proBNP and NDKA combination has a high discriminatory power in the detection of stroke with a sensitivity of 93% at a specificity of 100%. Both, sensitivity and specificity are improved using this combination compared to each single analyte.
  • Table 5 Multivariate Receiving-Operation-Characteristic analysis data for the NDKA and proBNP combination for Ischemic Stroke patients when compared to Control subjects
  • the proBNP and NDKA combination has a high discriminatory power in the detection of Ischemic stroke with a sensitivity of 95% at a specificity of 100%. Both, sensitivity and specificity are improved using this combination compared to each single analyte. • Control versus Hemorrhagic
  • the proBNP and NDKA combination has a high discriminatory power in the detection of hemorrhagic stroke with a sensitivity of 95% at a specificity of 98%. Both, sensitivity and specificity are improved using this combination compared to each single analyte.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to a method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps: (a) measuring the level of proBNP(1 -108), or of fragments of proBNP(1 -108) comprising a RAPRSP sequence (SEQ ID NO: 1 ), in a biological sample of the individual; (b) measuring the level of nucleoside diphosphate kinase A (NDKA) in a biological sample of the individual; (c) comparing the level of proBNP(1 -108), or of fragments of proBNP(1 -108), and the level of NDKA, with one or several cut-off values; (d) determining therefrom whether a stroke or a TIA has occurred in the individual.

Description

METHOD FOR THE IN VITRO DIAGNOSIS OF STROKE
Field of the invention
The present invention relates to methods and kits for the in vitro diagnosis of stroke.
Background of the invention
Stroke, also known as cerebrovascular accident (CVA), is one of the leading causes of mortality and morbidity with an estimated 700,000 patients diagnosed with stroke each year. Stroke currently ranks third in the cause of death in the U.S.A.
The term "stroke" encompasses two widely different clinical settings which it is of the utmost importance to distinguish. Ischemic stroke is thus usually caused by the blockage of blood vessels and is best treated by clot dissolving agents, such as t-PA, within three hours of symptom onset. In contrast, hemorrhagic stroke is caused by bleeding into the brain which forbids any treatment by anti-clotting agents, which could prove fatal.
Transient ischemic attack (TIA, often colloquially referred to as "mini stroke") is caused by the changes in the blood supply to a particular area of the brain, resulting in brief neurologic dysfunction that persists, by definition, for less than 24 hours; if symptoms persist then it is categorized as a stroke (see e.g. Transient Ischemic Attacks: Stroke (CVA): Merck Manual Home Edition). Patients diagnosed with a TIA are sometimes said to have had a warning for an approaching stroke. If the time period of blood supply impairment lasts more than a few minutes, the nerve cells of that area of the brain die and cause permanent neurologic deficit. One third of the people with TIA later have recurrent TIAs and one third have a stroke due to permanent nerve cell loss (Transient ischemic attack Mount Sinai Hospital, New York). Therefore, the identification of TIA is beneficial because these patients are at increased risk of future stroke.
The diagnosis of stroke, and the segmentation between ischemic and hemorrhagic stroke, in patients which present with symptoms indicative of stroke, such as sudden numbness or blindness, confusion, severe headaches, slurred speech, and partial paralysis, currently essentially relies on computed tomography (CT). CT, however, is not completely satisfying since it has an estimated sensitivity of less than 26% in diagnosing acute stroke (Chalela et al. (2007) Lancet 369:293-298), which is linked to a very poor performance in detecting ischemic stroke, with less than 33% sensitivity (Reynolds et al. (2003) CHn. Chem. 49:1733-1739). Magnetic resonance imaging (MRI) has been shown to be superior to CT in diagnosing acute stroke (84% sensitivity, Chalela et a/. (2007) Lancet 369:293-298), and particularly ischemic stroke. However MRI scanners are costly equipments and are not always available in the emergency room.
Accordingly there is still the need for alternative or complementary methods, in particular to CT, for diagnosing stroke and TIA.
In this respect, biochemical markers have been suggested as an aid in detecting stroke, in particular in view of the early detection of ischemic stroke.
S-100b (a marker of astrocytic activation) and neuron-specific enolase (NSE) are among the best characterized such markers (Jauch et al. (2006) Stroke 37:2508- 2513). Heart-type fatty acid binding protein(H-FABP) has also been considered as a promising marker (Lescuyer et al. (2005) MoI. Diagn. 9:1-7). However, it seems that the discriminatory power offered by these markers individually is not sufficient to be of clinical value.
It has thus been suggested to use panels combining several markers, such as S-100b, the B-type neurotrophic growth factor (BNGF), the von Willebrand factor (vWF), matrix metalloproteinase-9 (MMP-9) and monocyte chemotactic protein-1 (MCP-1 ), for diagnosing ischemic stroke (Reynolds et al. (2003) CHn. Chem. 49:1733-1739). Indeed, this panel was shown to provide a sensitivity of 92% at 93% specificity for ischemic stroke sample within 6 hours from symptom onset. Within 3 hours from onset however, sensitivity is of only 87%, which might be due to a too low individual sensitivity/specificity of the markers. Besides, measuring the level of 5 different markers might be seen as cumbersome, especially in the emergency room.
Accordingly, there is still the need for alternative marker panels to be used as such or to improve other multi-marker panels, either by increasing sensitivity/specificity or by enabling reducing the number of markers which levels have to be measured in panels. proBNP(1 -108), a precursor protein of 108 amino acids, is cleaved in vivo to yield (i) Brain Natriuretic Peptide (also referred to as BNP(32) or simply BNP), which consists of the 32 C-terminal amino acids of proBNP(1-108) and (ii) NT-proBNP, which consists of the 76 N-terminal amino acids of proBNP(1-108) (Giuliani et al. (2006) Clinical Chemistry 52:1054-61 ). Biologically, BNP is a blood pressure regulatory agent which is released mainly from the left cardiac ventricle in response to volume expansion and pressure overload. proBNP(1 -108) has been shown to be circulating in patients with severe heart failure (Hammerer-Lercher et al. (2008) Clinical Chemistry 54:5).
Nucleoside Diphosphate Kinase A (NDKA) has been shown to have a sensitivity of 70% and a specificity of 90% for stroke detection at a cut-off of 22 ng/μl as measured in the plasma of patients (Allard et al. (2005) Clin. Chem. 51 :2043- 2051 ).
Summary of the invention
The present invention arises from the unexpected finding, by the inventors, that proBNP(1-108) had a high discriminatory power (e.g. 90% sensitivity and 85 % specificity) in stroke detection.
Thus, the present invention relates to a method for the in vitro diagnosis of stroke and Transient ischemic attack (TIA) in an individual, comprising the following steps:
(a) measuring the level of proBNP(1 -108), or of fragments of proBNP(1-108) comprising a RAPRSP sequence (SEQ ID NO: 1 ), in a biological sample of the individual;
(b) measuring the level of nucleoside diphosphate kinase A (NDKA) in a biological sample of the individual;
(c) comparing the level of proBNP(1 -108), or of fragments of proBNP(1 -108), and the level of NDKA, with one or several cut-off values ;
(d) determining therefrom whether a stroke or a TIA has occurred in the individual.
In another embodiment of the invention, the above-defined method further comprises measuring the level of at least one marker of cardiovascular diseases. The present invention also relates to a kit for diagnosing stroke, comprising:
- at least one antibody suitable for detecting proBNP(1 -108), or of fragment of proBNP(1 -108) which comprise a RAPRSP sequence (SEQ ID NO: 1 ); and
- optionally at least one calibrator comprising proBNP(1 -108), or of fragment of proBNP(1 -108) which comprise a RAPRSP sequence (SEQ ID NO: 1 ), at least at a concentration of 1 pg/ml; and
- at least one antibody suitable for detecting NDKA; and - optionally at least one calibrator comprising NDKA, at least at a concentration of 7 ng/ml.
The present invention also relates to the use of:
- proBNP(1 -108), or of fragments of fragment of proBNP(1 -108) which comprise a RAPRSP sequence (SEQ ID NO: 1 ), and
- NDKA, for the in vitro diagnosis of stroke or TIA.
Detailed description of the invention
As intended herein "diagnosing" or establishing a "diagnosis" relates to determining if a stroke has occurred in an individual.
As intended herein "stroke" relates to all cerebrovascular accidents. In particular, the term "stroke" encompasses acute and chronic stroke as well as ischemic and hemorrhagic stroke.
Ischemic stroke is characterized by a partial or total occlusion of cerebral vessels which may lead to infarction and necrosis of cerebral tissues supplied by these vessels. In transient ischemic attack (TIA) the occlusion ceases spontaneously causing a dysfunction which lasts for no more than 24 hours.
Hemorrhagic stroke is characterized by an intracerebral haemorrhage generally from cerebral vessel rupture.
Preferably, the stroke according to the invention is selected from the group consisting of an ischemic stroke, a hemorrhagic stroke, or a transient ischemic attack (TIA). More preferably, the stroke as intended herein is acute ischemic stroke.
Advantageously, the method of the invention provides for early stroke diagnosis. Early stroke diagnosis is of particular importance in the case of ischemic stroke, since it is usually estimated that treating the occluded vessels within 3 hours of stroke symptoms onset will prevent most irreversible cerebral damages. Accordingly, it is preferred that the above defined step (a) is implemented within 6 hours, more preferably within 3 hours, and most preferably within 2 hours, after the onset of at least one symptom indicative of stroke in the individual.
The symptoms indicative of stroke are well known to one of skill in the art and notably encompass sudden numbness or blindness, confusion, severe headaches, slurred speech, and partial paralysis.
The individual is preferably a human. "proBNP(1 -108)" relates to the precursor BNP(32) and of NT-proBNP. As intended herein "proBNP(1-108)" encompasses all its natural variants, however it is preferred that proBNP(1 -108) is represented by SEQ ID NO: 4.
In vivo, proBNP(1-108) is often partially truncated, in particular it is deleted of one or more amino acids on the N-terminal side or optionally on the C-terminal side, for instance by circulating proteases, to form so-called "proBNP(1 -108) fragments". An example of such a proBNP(1 -108) fragment, the proBNP(3-108) fragment produced by cleavage by a dipeptidase, is described in Lam et al. (2007) J. Am. Coll. Cardiol. 49:1193-1202. It is believed that it is not only proBNP(1 -108) which is of diagnosis value but also its various natural fragments. Accordingly, the present invention not only relies on measuring the level of proBNP(1 -108) but also the level of fragments of proBNP(1-108).
The expression "proBNP(1 -108)" and "fragments of proBNP(1 -108)" also include any polypeptide having been subjected to at least one post-translational modification, such as phosphorylation, glycosylation or the like. For example, Schellenberger et al. (2006) Arch. Biochem. Biophys. 51 :160-6 have shown that proBNP(1 -108) is a glycoprotein which is O-glycosylated either entirely or in part.
As intended herein the fragments of proBNP(1-108) comprise the RAPRSP sequence (SEQ ID NO: 1 ). This RAPRSP sequence harbours the site of proBNP(1 - 108) which is cleaved in vivo to yield NT-proBNP and BNP(32). As such, the RAPRSP is specific of proBNP(1 -108) and cannot be found in BNP(32) nor in NT- proBNP, which are thus excluded from the definition of the fragments of proBNP(1 - 108) according to the invention.
It is further preferred that the fragments of proBNP(1 -108) according to the invention comprise a FGRKMDR sequence (SEQ ID NO: 2). This sequence is comprised in the BNP(32) part of proBNP(1 -108). Even more preferably, the fragments of proBNP(1 -108) comprise the whole sequence of BNP(32) (SEQ ID NO: 3).
"Nucleoside Diphosphate kinase A (NDKA)" is well known to one of skill in the art and is notably described in Allard et al. (2005) Clin. Chem. 51 :2043-2051. As intended herein "Nucleoside Diphosphate kinase A (NDKA)" encompasses all its natural variants, mutants, fragments, and the various glycosylated and phosphorylated forms thereof. By way of example NDKA is represented by SEQ ID NO: 5 and/or by Swissprot accession number P15531. Preferably, the above-defined natural variants or mutants of NDKA are such that they present at least 80%, more preferably at least 90% and most preferably at least 95% identity with SEQ ID NO: 5. As will be clear to one of skill in the art, are also within the scope of the invention methods according to the invention wherein the level of at least one further stroke marker is measured, kits according to the invention comprising antibodies to at least one further stroke marker and uses according to the invention of at least one further stroke marker. The expression "further stroke marker" relates to any biochemical marker, other than proBNP(1-108), fragments of proBNP(1 -108) as defined above, or NDKA, which level is indicative of stroke or TIA as defined above.
The expression "marker of cardiovascular diseases" relates to any marker useful for detecting or diagnosing a cardiovascular diseases. Such markers are well known to one of skill in the art. Preferably, the marker of cardiovascular diseases is selected from the group constituted of the C reactive protein (CRP) and cardiac troponin I (cTnl). Measuring the level of a marker of cardiovascular diseases may be advantageous in the the method of the invention since it enables excluding cardiovascular diseases as a cause for variation of the level of proBNP(1 -108).
Preferably, measuring or determining the level of proBNP(1 -108), of fragments of proBNP(1 -108), of NDKA, of the at least one further stroke marker, or of the at least one marker of cardiovascular diseases is determined using an immunoassay.
As intended herein an "immunoassay" relates to any method wherein the level of proBNP(1 -108), of fragments of proBNP(1 -108), of NDKA, of the at least one further stroke marker, or of the at least one marker of cardiovascular diseases, is determined using at least one compound (or ligand) specifically binding thereto. The compound (or ligand) specifically binding thereto can be of any type but it is preferred that it is an antibody, an aptamer, or a peptide obtained by phage display. Immunoassay methods are well known to one of skill in the art and may be carried out in accordance with various formats well-known to the one skilled in the art, for example in solid or homogeneous phase, in one or two steps, by a sandwich method or by a competitive method.
Preferably, the sandwich method in solid phase between 2 ligands, one being a capture ligand and the other being a detection ligand, will be used. This type of immunoassay is particularly well-known to one skilled in the art. For example, the article by Sefehan et al. (2007) CHn. Chem. 53:866-873 gives an example of a sandwich immunoassay (or immunometric assay at 2 sites) for assaying BNP(32) and proBNP(1 -108), each time using a pair of antibodies (an antibody immobilised in solid phase and an labelled antibody in detection).
The presence of the antigen in the biological sample is revealed by detection means, in particular a "detection ligand". A detection ligand, which is labelled, is able to bind to the captured antigen, by recognising an epitopic site which is different from that recognised by the capture ligand.
The term "labelled" refers both to a direct labelling and to an indirect labelling (for example, by means of other ligands, themselves directly labelled, or using reagents of a labelled "affinity pair", such as, but not exclusively, the labelled avidin- biotin pair, etc.).
In the case of the sandwich method, the capture ligand is preferably selected in such a way that it specifically recognises an epitope on the natural antigen of the patient, whilst the detection ligand is selected preferably in such a way that it specifically recognises another epitope on the natural antigen of the patient.
Preferably, the capture ligand is immobilised on a solid phase. By way of non- limiting examples of solid phase, microplates could be used, in particular polystyrene microplates, such as those sold by Nunc, Denmark. Solid particles or beads, paramagnetic beads, such as those produced by Dynal, Merck-Eurolab (France) (under the trademark EstaporTM) and Polymer Laboratories, or even polystyrene or polypropylene test tubes, glass, plastic or silicon chips, etc. may also be used.
ELISA assays, radioimmunoassays, or any other detection method may be used to reveal the presence of formed antigen-antibody complexes. Thus, different types of labelling of ligands in particular of antibodies, are possible (radioactive, ezymatic, fluorescent, etc.).
The detection may also be carried out by methods based on mass accumulation, such as surface plasmon resonance (SPR), by piezo-electric detection, but also by mass spectrometry or any other methods defined as enabling the study of a ligand-antigen-type interaction in the absence of a second labelled ligand.
The term "specific", when it refers to recognition of a ligand or binding of a ligand to a target, means that the ligand interacts with the target without interacting substantially with another target which does not structurally resemble the target.
An "antibody" as intended herein relates to antibodies belonging to any species, such as human, mouse, rat, rabbit, goat, or camelidae species. The antibody can also be a chimeric antibody, i.e. an antibody which comprises parts originating from different species. Preferred chimeric antibodies are so-called "humanized" antibodies, wherein the constant parts (CH and CL) are of human origin and the variable parts (VH and VL) are of another species, such as mouse for instance. The antibody of the invention can be produced by any method known the man skilled in the art, such as by animal immunization, or by recombinant or synthetic methods for instance. Besides, an "antibody" according to the invention also encompasses antibody fragments which comprise at least one of the paratopes of said antibody, such as Fab, F(ab')2, scFv fragments as well as camelidae single- chain antibodies. The antibody of the invention can be a polyclonal antibody, in particular a monospecific polyclonal antibody, or a monoclonal antibody.
"Aptamers" are well-known by the one skilled in the art. Aptamers are compounds of a nucleotide, in particular a ribonucleotide or desoxyhbonucleotide, or a peptide nature able to bind specifically to a target, in particular a protein target. The aptamers of a nucleotide nature and the production thereof are described, in particular, by Ellington et al. (1990) Nature 346:818-22 and Bock et al. (1992) Nature 355:564-6. The aptamers of a peptide nature and the production thereof are described, in particular, by Hoppe-Seyler et al. (2000) J. MoI Med. 78:426-30.
"Phage display" denotes a technique for selecting polypeptide ligands expressed on the capsid of a bacteriophage and encoded by a nucleic sequence inserted into the capsid encoding gene. This method is well known by the one skilled in the art and is described, in particular, by Scott & Smith (1990) Science 249:386- 390, and Marks et a/. (1991 ) J. MoI. Biol. 222:581 -597. Preferably, the polypeptide obtainable by phage display is an scFv-type polypeptide (single-chain variable fragment). This technique is described, in particular, by Winter et al. (1994) Annu. Rev. Immunol. 12:433-455.
Preferably, the above-defined immunoassay comprises an antibody targeting an epitope which comprises the RAPRSP sequence (SEQ ID NO: 1 ). More preferably, the antibody is secreted by the hybridoma deposited at the CNCM (Collection Nationale de Cultures de Microorganismes, lnstitut Pasteur, 25, rue du Docteur Roux, 75 724 Paris Cedex 15, France) under the Budapest Treaty on April 29, 2005, under reference number I-3073. Such an antibody is notably described in the international publication WO 2004/014952. This antibody is advantageous, in that it enables the specific detection of proBNP(1-108) and of all the fragments of proBNP(1-108) according to the invention, with the notable exception of BNP(32), NT-proBNP and their respective fragments, thereby ensuring obtaining the full diagnosis benefits of proBNP(1-108) and its various fragments.
Preferably also, the immunoassay comprises an antibody targeting an epitope which comprises the FGRKMDR sequence. More preferably, the antibody is secreted by the hybhdoma deposited by Bio-Rad (3 boulevard Raymond Poincare, 92430 Marnes Ia Coquette, France) at the CNCM (Collection Nationale de Cultures de Microorganismes, lnstitut Pasteur, 25, rue du Docteur Roux, 75 724 Paris Cedex 15, France) under the Budapest Treaty on April 13, 2007, under reference number I- 3746. Such an antibody is notably described in international application PCT/EP2008/060188.
Advantageously, the antibody targeting an epitope which comprises the RAPRSP sequence (SEQ ID NO: 1 ) and the antibody targeting an epitope which comprises the FGRKMDR sequence are combined in a same immunoassay, thereby enabling the specific detection of proBNP(1 -108) or of fragments of proBNP(1 -108) according to the invention.
Preferably, NDKA level is measured using an ELISA method as generally described in international application WO 2005/029088 and in Allard et a/. (2005) Clin. Chem. 51 :2043-2051.
Preferably, where proBNP(1 -108), or of fragments of proBNP(1 -108) are concerned, the cut-off value as defined above is of at least the mean level of proBNP(1-108), or of fragments of proBNP(1 -108) according to the invention in biological samples obtained from an apparently healthy population of individuals. More preferably, the above-defined cut-off value is of at least the value corresponding to the 75th percentile, the 95th percentile, or the 99th percentile of the levels of proBNP(1 -108), or of fragments of proBNP(1 -108) according to the invention obtained from an apparently healthy population of individuals. Most preferably, this cut-off value is of at least 0, 1 , 2, 3, 5, 10, 50 or 100 pg/ml. Where the cut-off value is of at least 0 pg/ml this means that the above defined steps a) and b) of the method of the invention consist simply in determining whether proBNP(1 -108), or fragments of proBNP(1-108), as defined above are present in the biological sample of the individual.
Similarly, where NDKA is concerned, the cut-off value as defined above is preferably of at least the mean level of NDKA in biological samples obtained from an apparently healthy population of individuals. More preferably, the above-defined cutoff value is of at least the value corresponding to the 75th percentile, the 95th percentile, or the 99th percentile of the levels of NDKA obtained from an apparently healthy population of individuals. Most preferably, this cut-off value is of at least 5, 10, 15, or 20 ng/ml.
Similarly, where the at least further stroke marker is concerned, the cut-off value as defined above is preferably of at least the mean level of said at least one further stroke marker in biological samples obtained from an apparently healthy population of individuals.
It is well within the ordinary skills of one of skill in the art to determine cut-off values according to the invention. In particular, care should preferably taken to measure the level of proBNP(1 -108), of fragments of proBNP(1 -108) according to the invention, or of the at least one further stroke marker, in biological samples which are of the same nature. As intended herein, "an apparently healthy population of individuals" relates to individuals which preferably present none of the symptoms indicative of stroke as defined above.
Where the level of proBNP(1 -108), or of fragments of proBNP(1 -108), and the level of the at least one further stroke marker, are compared with one or several cutoff values, this means that the level of proBNP(1 -108), or of fragments of proBNP(1 - 108), on one hand, and the level of the at least one further stroke marker, on the other hand, can be each compared to respective cut-off values, or that they can be both compared to a single cut-off value.
It is preferred that the level of NDKA (and optionally also that of the at least one further stroke marker or marker of cardiovascular diseases) is measured in the same biological sample as that in which the level of proBNP(1 -108), or of fragments of proBNP(1 -108), is measured.
As intended herein, the expression "biological sample" includes both the sample as taken and the sample which has been subjected to various treatments, in particular to render it suitable for use in the processes and methods according to the invention. The biological sample according to the invention can be of any type, however it is preferred that the biological sample is selected from the group constituted of a blood sample, a serum sample, a plasma sample, a cerebrospinal fluid sample, a urine sample and a saliva sample. Examples
Example 1
1. Methods a. Samples
The levels of proBNP(1-108) and NDKA were determined in 70 serum samples obtained from individuals in whom a stroke has occurred less than 3 hours after onset (15 hemorrhagic stroke samples (HM) and 55 ischemic stroke samples (IM)) and in 148 control serum samples from apparently healthy individuals.
b. Marker level determination
The proBNP(1 -108) level was determined using the BioPlex™2200 proBNP(1 -108) assay (Bio-Rad).
The BioPlex™2200 combines multiplex, magnetic bead and flow cytometry technologies to provide multi-analyte detection on a fully automated random access platform. Magnetic particles (8 μm diameter, carboxyl-modified surface) are dyed with 2 fluorophores (classification dyes, CL1 and CL2) which emit at distinct wavelengths and adsorb significantly at 635 nm. The reporter fluorophore, β-phycoerythrin (PE) was chosen for its high molar extinction coefficient, quantum yield, resistance to photobleaching, lack of self-quenching and stability. The detector simultaneously measures light at 3 wavelengths: the 2 classification dyes and the reporter dye.
The BioPlex™2200 proBNP(1 -108) assay is a two-step sandwich fluorescence immunoassay. In a first step, the BioPlex™2200 system combines 50 μl_ of patient sample, magnetic dyed beads coated with the anti-proBNP(1 -108) monoclonal antibody secreted by the hybhdoma deposited at the CNCM under reference number I-3073 and assay buffer into a reaction vessel. Then, after 11 minutes of incubation and wash cycles, anti-human BNP monoclonal antibody secreted by the hybridoma deposited at the CNCM under reference number I-3746 conjugated to phycoerythrin (PE) is added and incubated for 2 minutes. After removal of excess conjugate, the bead mixture is passed through the detector which identifies the dyed beads and the amount of antigens captured on the beads by the fluorescence of PE. After calibration using a set of 6 distinct calibrators, the 3 levels of quality controls and patient samples results are expressed in pg/mL. Two Quality Control beads are also tested with each sample to enhance the integrity of the overall system.
The NDKA level was determined using an ELISA method as generally described in international application WO 2005/029088 and in Allard et a/. (2005) Clin. Chem. 51 :2043-2051.
c. Statistical analysis
Distribution of biomarkers according to patient status was represented by boxplot representation, which is a convenient way of graphically depicting groups of numerical data through their five-number summaries (the smallest observation, lower quartile (Q1 ), median (Q2), upper quartile (Q3), and largest observation).
Data have been normalized using the Box-Cox method to follow a Gaussian distribution and enable statistical analysis (Box, G. E. P. and Cox, D. R. (1964) An analysis of transformations. JRSS B 26, 211-246).
Differential analysis between the control and stroke samples were done using the following statistical tests: the Wilcoxon Rank Sum Test (Wilcoxon, F. (1945). Individual comparisons by ranking methods. Biometrics, 1 , 80-83) which is non- parametric (requires no assumption of statistical distribution and which can be an alternative to Student's t-test) and the Welch's test which is an adaptation of Student's t-test intended for use with two samples having possibly unequal variances. The analysis also includes the adjusted (corrected) versions of these tests by the Benjamini/Hochber method (Benjamini and Y. Hochberg (1995). Controlling the False Discovery Rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B. Vol. 57: 289-300) was also performed.
The diagnostic performance of the markers was characterized by two indices: sensitivity (ability to detect the diseased population) and specificity (ability to detect the control population). The result of a diagnostic test can be further characterized by determining the area under the curve (AUC) of a ROC (receiver operating characteristic) analysis. The ROC curves are a graphical visualization of the reciprocal relation between the sensitivity (Se) and the specificity (Sp) of a test for various concentrations (M. H. Zweig and G. Campbell (1993). "Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine". Clinical chemistry 39 (8): 561-57). Multivariate ROC curve analysis (mROC) was also performed for the proBNP (1-108) and NDKA marker combination, when comparing control to ischemic stroke patients and control to hemorrhagic stroke patients, using a mROC software well described by Kramar et al. (Comput. Methods Programs Biomed. 2001 ;66:199-207; Revue d'Epidemiologie et Sante Publique 1999;47:376-83). mROC is a dedicated program calculating the linear combination (Su et al. Journal of the American Statistical Association 1993;88:1350-1355), to maximize the AUC (Area Under the Curve) ROC for all markers selected (Staack et al. BMC Urology 2006;6:1 -12). The equation for the respective combination is provided and can be used as a new virtual marker. For a marker combination and for a sample selected, the cut-off is the result value of the linear equation corresponding and calculated by the mROC program:
Marker combination cut-off = a x Markeri + b x Marker2 where a and b are calculated coefficients and Markeri and Marker2 are individual marker cut-off values.
2. Results a) Differential analysis
The statistical significance of the difference in NDKA and proBNP(1 -108) levels between stroke samples and control samples was determined:
Table 1 : Differential analysis between concentrations determined from the Control and the Stroke populations for NDKA and proBNP markers
In this table, the difference in concentrations between the stroke samples and the control samples is statistically significant for both the proBNP and the NDKA markers are statistically significant with very low p-values (10 ,-4\ ). b) Univariate ROC curve analysis
• The NDKA marker
Table 2: Receiving-Operation-Characteristic analysis data for NDKA for Stroke patients when compared to Control subjects
The NDKA marker has a high discriminatory power in the prediction of stroke with a sensitivity of 90%, a specificity of 91.7% (Area Under the ROC curve (AUC): 0.952). Moreover, this discriminatory power is very high for both the ischemic and the hemorrhagic stroke patients compared to the control subjects.
• The proBNP marker
Table 3: Receiving-Operation-Characteristic analysis data for proBNP for Stroke patients when compared to Control subjects
The proBNP marker has a high discriminatory power in the prediction of cerebrovascular accident with a sensitivity of 88%, a specificity of 93.8% and an area under the ROC curve (AUC) of 0.952. Moreover, this discriminatory power is very high for both the ischemic and the hemorrhagic stroke patients compared to the control subjects with respective AUC of 0.95 and 0.962. c) Multivariate ROC curve analysis
• Control versus Stroke
Table 4: Multivariate Receiving-Operation-Characteristic analysis data for the NDKA and proBNP combination for Stroke patients when compared to Control subjects
Linear equations for decision rules : Z = 0.479*[proBNP] + 2.815*[NDKA]
The proBNP and NDKA combination has a high discriminatory power in the detection of stroke with a sensitivity of 93% at a specificity of 100%. Both, sensitivity and specificity are improved using this combination compared to each single analyte.
• Control versus Ischemic
Table 5: Multivariate Receiving-Operation-Characteristic analysis data for the NDKA and proBNP combination for Ischemic Stroke patients when compared to Control subjects
Linear equations for decision rules: Z = 3.782*[NDKA] + 0.526*[proBNP]
The proBNP and NDKA combination has a high discriminatory power in the detection of Ischemic stroke with a sensitivity of 95% at a specificity of 100%. Both, sensitivity and specificity are improved using this combination compared to each single analyte. • Control versus Hemorrhagic
Table 6: Multivariate Receiving-Operation-Characteristic analysis data for the NDKA and proBNP combination for Hemorrhagic Stroke patients when compared to Control subiects
Cut-off determined
Ctrl Vs HM from normalized Se Sp AUC IC 95% values
NDKA, proBNP 6.589 95% 98% 0.993 0.962 - 0.999
Linear equations for decision rules: Z = 6.906*[NDKA] + 0.200*[proBNP]
The proBNP and NDKA combination has a high discriminatory power in the detection of hemorrhagic stroke with a sensitivity of 95% at a specificity of 98%. Both, sensitivity and specificity are improved using this combination compared to each single analyte.

Claims

Claims
1. A method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps:
(a) measuring the level of proBNP(1 -108), or of fragments of proBNP(1-108) comprising a RAPRSP sequence (SEQ ID NO: 1 ), in a biological sample of the individual;
(b) measuring the level of nucleoside diphosphate kinase A (NDKA) in a biological sample of the individual;
(c) comparing the level of proBNP(1 -108), or of fragments of proBNP(1 -108), and the level of NDKA, with one or several cut-off values ;
(d) determining therefrom whether a stroke or a TIA has occurred in the individual.
2. The method according to claim 1 , wherein the fragments of proBNP(1 -108) further comprise a FGRKMDR sequence (SEQ ID NO: 2).
3. The method according to claim 1 or 2, wherein the fragments of proBNP(1 -108) comprise the sequence of BNP(32) (SEQ ID NO: 3).
4. The method according to any of claims 1 to 3, wherein the stroke is selected from the group consisting of an ischemic stroke and a hemorrhagic stroke.
5. The method according to any of claims 1 to 4, wherein step (a) is implemented within 6 hours after the onset of at least one symptom indicative of stroke in the individual.
6. The method according to any of claims 1 to 5, wherein the level of proBNP(1-108), or of fragments of proBNP(1 -108), is measured using an immunoassay.
7. The method according to claim 6, wherein the immunoassay comprises an antibody targeting an epitope which comprises the RAPRSP sequence (SEQ ID NO: 1 )-
8. The method according to claim 7, wherein the antibody is secreted by the hybhdoma deposited at the CNCM (Paris, France) under the Budapest Treaty on April 29, 2005, under reference number 1-3073.
9. The method according to any of claims 6 to 8, wherein the immunoassay comprises an antibody targeting an epitope which comprises the FGRKMDR sequence (SEQID NO: 2).
10. The method according to claim 9, wherein the antibody is secreted by the hybhdoma deposited at the CNCM (Paris, France) under the Budapest Treaty on April 13, 2007, under reference number I-3746.
11. The method according to any of claims 1 to 10, wherein the NDKA level is measured using an immunoassay.
12. The method according to any of claims 1 to 11 , wherein the level of NDKA is measured in the same biological sample as that in which the level of proBNP(1-108), or of fragments of proBNP(1 -108), is measured.
13. The method according to any of claims 1 to 12, wherein the biological sample is selected from the group constituted of a blood sample, a serum sample, a plasma sample, a cerebrospinal fluid sample, a urine sample and a saliva sample.
14. The method according to any of claims 1 to 13, further comprising measuring the level of at least one marker of cardiovascular diseases.
15. The method according to claim 14, wherein the at least one marker of cardiovascular diseases is selected from the group consisting of CRP and cTnl.
16. A kit for diagnosing stroke or TIA, comprising:
- at least one antibody suitable for detecting proBNP(1 -108), or of fragment of proBNP(1 -108) which comprise a RAPRSP sequence (SEQ ID NO: 1 ); and
- at least one antibody suitable for detecting NDKA.
17. The use of:
- proBNP(1-108), or of fragments of fragment of proBNP(1-108) which comprise a
RAPRSP sequence (SEQ ID NO: 1), and
-NDKA, for the in vitro diagnosis of stroke or TIA.
EP09786393.0A 2009-01-30 2009-01-30 Method for the in vitro diagnosis of stroke Active EP2411804B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2009/051978 WO2010086697A1 (en) 2009-01-30 2009-01-30 Method for the in vitro diagnosis of stroke

Publications (2)

Publication Number Publication Date
EP2411804A1 true EP2411804A1 (en) 2012-02-01
EP2411804B1 EP2411804B1 (en) 2015-08-26

Family

ID=41100580

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09786393.0A Active EP2411804B1 (en) 2009-01-30 2009-01-30 Method for the in vitro diagnosis of stroke

Country Status (6)

Country Link
US (1) US8486652B2 (en)
EP (1) EP2411804B1 (en)
JP (1) JP5589000B2 (en)
AU (1) AU2009339152B2 (en)
CA (1) CA2751090A1 (en)
WO (1) WO2010086697A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290924B1 (en) * 2011-12-01 2021-10-13 Roche Diagnostics GmbH Nt-proanp and nt-probnp for the diagnosis of stroke
GB2497138A (en) 2011-12-02 2013-06-05 Randox Lab Ltd Biomarkers for stroke and stroke subtype diagnosis.
US9366678B2 (en) 2012-10-25 2016-06-14 Wisconsin Alumni Research Foundation Neutron encoded mass tags for analyte quantification
WO2014188408A1 (en) 2013-05-20 2014-11-27 Beyond Verbal Communication Ltd Method and system for determining a pre-multisystem failure condition using time integrated voice analysis
GB201309928D0 (en) 2013-06-04 2013-07-17 Randox Lab Ltd Method
JP2015137272A (en) * 2014-01-24 2015-07-30 東ソー株式会社 Novel peptide and method for detecting disease
WO2016048388A1 (en) 2014-09-26 2016-03-31 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
US10456059B2 (en) 2015-04-06 2019-10-29 Forest Devices, Inc. Neuorological condition detection unit and method of using the same
GB201619823D0 (en) 2016-11-23 2017-01-04 Randox Laboratories Ltd And Teoranta Randox GFAP accumulating stroke
EP3579418A4 (en) 2017-08-07 2020-06-10 Shenzhen Goodix Technology Co., Ltd. Vector quantization digital-to-analog conversion circuit for oversampling converter
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
CN112808550B (en) * 2020-12-28 2021-10-01 青岛理工大学 Deteriorated immune bionic protective interface for marine engineering and preparation method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233949D1 (en) * 2001-08-20 2009-11-19 Biosite Inc DIAGNOSTIC MARKERS FOR STROKE AND HARNTRAUMA AND METHOD OF USE THEREOF
US20040219509A1 (en) * 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
FR2843396B1 (en) * 2002-08-07 2005-04-15 Bio Rad Pasteur SPECIFIC ANTIBODIES FOR THE DIAGNOSIS OF HEART FAILURE
US7341838B2 (en) * 2003-04-17 2008-03-11 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
DK2341350T3 (en) 2003-09-20 2018-02-05 Electrophoretics Ltd DIAGNOSTIC PROCEDURE FOR BRAKE INJURY-RELATED DISORDERS BASED ON DJ-1 DETECTION
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
NZ577805A (en) * 2006-12-05 2012-09-28 Decode Genetics Ehf Genetic markers for risk management of cardiac arrhythmia
WO2010012509A1 (en) * 2008-08-01 2010-02-04 Bio-Rad Pasteur Method for the in vitro diagnosis of stroke
CN102257386B (en) * 2008-10-24 2014-12-31 B.R.A.H.M.S有限公司 Prognosis and risk assessment in stroke patients by determining the level of marker peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010086697A1 *

Also Published As

Publication number Publication date
JP2012516437A (en) 2012-07-19
US20120028824A1 (en) 2012-02-02
AU2009339152B2 (en) 2015-11-19
EP2411804B1 (en) 2015-08-26
AU2009339152A1 (en) 2011-09-15
US8486652B2 (en) 2013-07-16
CA2751090A1 (en) 2010-08-05
WO2010086697A1 (en) 2010-08-05
JP5589000B2 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
EP2411804B1 (en) Method for the in vitro diagnosis of stroke
AU2009275875B2 (en) Method for the in vitro diagnosis of stroke
WO2010012834A1 (en) Method for the in vitro diagnosis of stroke
CN102203621B (en) Prognostic biomarkers for the development of primary chronic kidney disease
EP2776839B1 (en) Dynamic of sflt-1 or endoglin/plgf ratio as an indicator for imminent preeclampsia and/or hellp syndrome
CN107064525A (en) For determine have a heart disease or generation under a cloud or the patient that has a heart disease in amino terminal proANP method
EP1664769B1 (en) Assay for detecting atrial and brain natriuretic peptide prohormones
CN101410716A (en) Means and methods for identifying acute and chronic myocardial necrosis in symptomatic patients
CN113956355B (en) Anti-human Brain Natriuretic Peptide (BNP) rabbit monoclonal antibody and application thereof
CN101144811A (en) Biochemical markers for acute pulmonary embolism
EP3132268B1 (en) Immunoassay for the detection of chromogranin a
CN101819208A (en) Kit for detecting brain natriuretic peptide by nano microsphere immunonephelometry
US8524459B2 (en) Method for the in vitro diagnosis of stroke
KR20140030188A (en) Method for determining the risk of cardiovascular events using igfbp fragments
CN112166323A (en) Direct immunoassay measurement of autoantibodies
JP5795256B2 (en) Methods for in vitro diagnosis of stroke
CN115594763B (en) Hybridoma cell lines 10B9E3-1 and 2D5C12-1 and applications of their secreted antibodies
CA2732445A1 (en) Method for the in vitro diagnosis of stroke
CN108226529A (en) A kind of NT-proBNP detection kits, method of preparation and use based on bimolecular fluorescence complementary technology
AU2016201172B2 (en) Diagnosis of cardiovascular disease
CN108267595A (en) A kind of Myo detection kits, method of preparation and use based on bimolecular fluorescence complementary technology
WO2014007367A1 (en) Method for detecting or assaying two kinds of substances in same sample
HK1229425B (en) Immunoassay for the detection of chromogranin a
HK1229425A1 (en) Immunoassay for the detection of chromogranin a
HK1113819A (en) Means and methods for the differentiation of cardiac and pulmonary causes of shortness of breath

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110729

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

17Q First examination report despatched

Effective date: 20120907

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20141006

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150331

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LARUE, CATHERINE

Inventor name: GUEGAN, JOHANN

Inventor name: GIULIANI, ISABELLE

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 745488

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009033215

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 745488

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150826

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151126

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151127

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20150826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151228

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151226

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009033215

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160131

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20160530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160130

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160131

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160131

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20090130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150826

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20210624 AND 20210630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230124

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230124

Year of fee payment: 15

Ref country code: DE

Payment date: 20230127

Year of fee payment: 15

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602009033215

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20240130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240130

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240131

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240801